(OAKVILLE, Ontario) May 24, 2023 – FORUS Therapeutics Inc (“FORUS”) and the pan-Canadian Pharmaceutical Alliance (“pCPA”) have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
“We are very pleased to have successfully concluded the negotiation process with the pCPA. This is a significant milestone to ensure that Canadian MM patients have broad and equitable access to XPOVIO,” said Kevin Leshuk, President and CEO of FORUS. “The FORUS team has already achieved early access through private payer reimbursement for patients and we now look forward to working with jurisdictions across Canada to secure coverage from publicly funded drug plans.”
“This is exciting news for the MM community across Canada,” said Martine Elias, MSc, Executive Director, Myeloma Canada. “We hope the provinces move as quickly as possible. MM is incurable and effective treatment options are needed to meet the evolving needs of patients. This new treatment regimen provides patients with a unique, effective oral option and meets many of the treatment needs of the myeloma patient community.”
- The pCPA agreement will support the public listings and reimbursement of XPOVIO.
- XPOVIO represents the first new drug class for the treatment of early relapsed or refractory multiple myeloma introduced into Canada within the last 7 years.
- XPOVIO, a Selective Inhibitor of the Nuclear Export (SINE) protein XPO1, offers myeloma treaters and patients a unique mechanism of action that works effectively with other treatments and provides rapid and durable responses.
About FORUS Therapeutics
FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. Our mission is to bring solutions to cancer patients, caregivers, physicians and our partners by accelerating unique and important treatments that meaningfully enhance life.
For Further Information and Media Inquiries: Kevin Leshuk, President and CEO, FORUS Therapeutics Inc. (media@forustherapeutics.com)
Read on LinkedIn
Read more on newsfile